

VRL/SEC/BSE_NSE

February 9th, 2015

<p>National Stock Exchange of India Ltd. 5th Floor , Exchange Plaza Bandra (E), Mumbai- 400 051</p>	<p>Dept. of Corporate Services The Stock Exchange, Mumbai 25th Floor ,Phiroze Jeejeebhoy Towers Dalal Street, Mumbai</p>
---	--

Sub. : Venus announces issuance of Indian Patent for Vancoplus

Dear Sir/Madam,

This is to inform you that Venus Remedies Limited has announced that the Indian Patent Office (IPO) has issued product patent grant for its unique research product, Vancoplus. It is valid till 2025.

Vancoplus is a novel antibiotic adjuvant entity highly effective against notorious (MRSA) strain and multi-drug resistant microbes primarily responsible for causing infections such as Meningitis, Pneumonia, Typhoid, Septicemia, Urinary Tract Infection, Skin infections and Staphylococcal Endocarditis. It is also active against different mechanisms of resistance such as cell membrane impermeability, efflux pumps, biofilms, which no other existing therapeutic options available in the market are able to address.


It took Venus Medicine Research Centre (VMRC) more than seven years to develop this product. It is one the best and safest option to address MRSA, VISA, hGISA and mixed bacterial infections of gram negative & gram positive pathogens.

The total market size of MRSA in the world accounts for \$ 9 billion. At present, it is growing with CAGR of 4.8 per cent which is estimated to reach to 12.4 per cent by 2017. In India, Vancoplus would have an addressable market of Rs. 214 crore by 2018-19.

Vancoplus has already been launched in the Indian market and till date approx 80,000 patients have been cured with it. It has received an overwhelming response from the medical fraternity in India. The company has conducted clinical trials on large patient population to prove the clinical efficacy and safety, which is further validated by publications in peer reviewed journals. Venus has more than 15 papers on this product.

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I,
Panchkula (Hry.) 134113, India
Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com



Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566
Unit-II :
Hill Top Industrial Estate, Jharmajri EPIR, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272
Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany

Venus has already received patent grant for Vancoplus from more than 18 countries including USA, Japan, South Africa, New Zealand, Ukraine, Australia and South Africa. The Company is into advance level of discussions with few MNCs for out-licensing of this product.

Yours faithfully,
for **VENUS REMEDIES LIMITED**

Ramanjit

Ramanjit Kaur
Deputy Manager
Corporate Communication



VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I,
Panchkula (Hry.) 134113, India
Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com



Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566
Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272
Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany

CIN - L24232CH1989PLC009705